SPAS(SH:603168) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-09-27 00:45Core Viewpoint - Shanghai Jingxing plans to reduce its shareholding in Shalifei Pharmaceutical Co., Ltd. due to funding needs, with a total reduction of up to 11,277,750 shares, accounting for 3% of the company's total share capital [2][3]. Shareholding Situation - As of September 26, 2025, Shanghai Jingxing holds 12,982,726 unrestricted circulating shares, representing 3.4535% of Shalifei's total share capital [2]. Reduction Plan Details - The reduction will occur in two phases: - Up to 3,759,250 shares through centralized bidding from October 10, 2025, to January 9, 2026, not exceeding 1% of the total share capital [3]. - Up to 7,518,500 shares through block trading during the same period, not exceeding 2% of the total share capital [3]. - The total planned reduction is capped at 11,277,750 shares, which is 3% of the total share capital [3]. Compliance and Commitments - Shanghai Jingxing has made prior commitments regarding shareholding and reduction methods, including a lock-up period of 12 months post-IPO and a commitment to not sell shares below the IPO price during the first two years after the lock-up [7][9]. - The company will adjust the reduction numbers in case of stock changes such as stock dividends or capital increases [6]. Regulatory Compliance - The reduction plan complies with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Shanghai Stock Exchange's guidelines [15].